Angiotensin-(1-7) decreases inflammation and lung damage caused by betacoronavirus infection in mice

Inflamm Res. 2024 Nov;73(11):2009-2022. doi: 10.1007/s00011-024-01948-8. Epub 2024 Sep 18.

Abstract

Objective: Pro-resolving molecules, including the peptide Angiotensin-(1-7) [Ang-(1-7)], have potential adjunctive therapy for infections. Here we evaluate the actions of Ang-(1-7) in betacoronavirus infection in mice.

Methods: C57BL/6J mice were infected intranasally with the murine betacoronavirus MHV-3 and K18-hACE2 mice were infected with SARS-CoV-2. Mice were treated with Ang-(1-7) (30 µg/mouse, i.p.) at 24-, 36-, and 48-hours post-infection (hpi) or at 24, 36, 48, 72, and 96 h. For lethality evaluation, one additional dose of Ang-(1-7) was given at 120 hpi. At 3- and 5-days post- infection (dpi) blood cells, inflammatory mediators, viral loads, and lung histopathology were evaluated.

Results: Ang-(1-7) rescued lymphopenia in MHV-infected mice, and decreased airways leukocyte infiltration and lung damage at 3- and 5-dpi. The levels of pro-inflammatory cytokines and virus titers in lung and plasma were decreased by Ang-(1-7) during MHV infection. Ang-(1-7) improved lung function and increased survival rates in MHV-infected mice. Notably, Ang-(1-7) treatment during SARS-CoV-2 infection restored blood lymphocytes to baseline, decreased weight loss, virus titters and levels of inflammatory cytokines, resulting in improvement of pulmonary damage, clinical scores and lethality rates.

Conclusion: Ang-(1-7) protected mice from lung damage and death during betacoronavirus infections by modulating inflammation, hematological parameters and enhancing viral clearance.

Keywords: Angiotensin-(1–7); Coronavirus; Covid-19; MHV-3; SARS-CoV-2.

MeSH terms

  • Angiotensin I* / pharmacology
  • Angiotensin I* / therapeutic use
  • Animals
  • COVID-19*
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / pathology
  • Cytokines* / blood
  • Female
  • Inflammation / drug therapy
  • Lung* / drug effects
  • Lung* / pathology
  • Lung* / virology
  • Lymphopenia / drug therapy
  • Male
  • Mice
  • Mice, Inbred C57BL*
  • Murine hepatitis virus / drug effects
  • Peptide Fragments* / pharmacology
  • Peptide Fragments* / therapeutic use
  • SARS-CoV-2 / drug effects
  • Viral Load / drug effects

Substances

  • angiotensin I (1-7)
  • Angiotensin I
  • Peptide Fragments
  • Cytokines